CD274 and non-small cell lung carcinoma: The SNPs of PD-L1 may be used to predict the clinical outcomes of NSCLC patients receiving 1st line chemotherapy, thereby helping to identify subgroups of patients who would benefit from chemotherapy and to save patients from unnecessary toxicities.